OGT releases new whitepaper for aiding biomarker discovery

Added: (Fri Jan 27 2012)

Pressbox (Press Release) - ‘Autoantibody biomarker panels for improved disease diagnosis’

Oxford, UK – 24 January 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has released a new whitepaper entitled ‘Autoantibody biomarker panels for improved disease diagnosis’. The free-to-download document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development. Autoantibodies are produced by the host immune system and as such are often detectable during the early stages of disease onset. In addition, they are stable, abundant, highly specific and easily purified from serum, making them ideal candidates for use in disease detection. The issues surrounding the use of autoantibodies as biomarkers are discussed in detail in the whitepaper, including their relative advantages, selection of the most appropriate discovery technology and choosing between strategies for in-house or outsourced discovery.

To learn more, download the whitepaper, or alternatively visit OGT’s new website for more details about the company’s clinical genetics, genomic services and diagnostic biomarker solutions.